Incyte Biosciences Japan G.K. (INCY) on Monday reported the approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi (tafasitamab) in combination with rituximab and lenalidomide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results